BRKR RSI Chart
Last 7 days
-0.9%
Last 30 days
-9.5%
Last 90 days
-8.3%
Trailing 12 Months
0.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 3.0B | 0 | 0 | 0 |
2023 | 2.6B | 2.7B | 2.8B | 3.0B |
2022 | 2.5B | 2.5B | 2.5B | 2.5B |
2021 | 2.1B | 2.3B | 2.4B | 2.4B |
2020 | 2.0B | 2.0B | 2.0B | 2.0B |
2019 | 1.9B | 2.0B | 2.0B | 2.1B |
2018 | 1.8B | 1.8B | 1.9B | 1.9B |
2017 | 1.6B | 1.7B | 1.7B | 1.8B |
2016 | 1.6B | 1.6B | 1.6B | 1.6B |
2015 | 1.7B | 1.7B | 1.7B | 1.6B |
2014 | 1.9B | 1.9B | 1.9B | 1.8B |
2013 | 1.8B | 1.8B | 1.8B | 1.8B |
2012 | 1.7B | 1.7B | 1.7B | 1.8B |
2011 | 1.4B | 1.5B | 1.6B | 1.7B |
2010 | 1.2B | 1.2B | 1.3B | 1.3B |
2009 | 0 | 0 | 0 | 1.1B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 04, 2024 | requardt hermann fritz | sold | -1,350,900 | 90.0599 | -15,000 | - |
Mar 04, 2024 | requardt hermann fritz | acquired | 330,750 | 22.05 | 15,000 | - |
Feb 28, 2024 | busse falko | sold | -2,403,890 | 85.4808 | -28,122 | president, biospin group |
Feb 28, 2024 | busse falko | acquired | 739,156 | 26.2839 | 28,122 | president, biospin group |
Feb 22, 2024 | prause burkhard | sold | -1,276,070 | 83.3 | -15,319 | pres. & ceo, bruker best |
Feb 22, 2024 | prause burkhard | acquired | 235,292 | 43.1728 | 5,450 | pres. & ceo, bruker best |
Jan 05, 2024 | requardt hermann fritz | acquired | - | - | 2,377 | - |
Jan 05, 2024 | rosenthal bob | acquired | - | - | 2,377 | - |
Jan 05, 2024 | packer richard a | acquired | - | - | 2,377 | - |
Jan 05, 2024 | ma philip | acquired | - | - | 2,377 | - |
Which funds bought or sold BRKR recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 16, 2024 | FSA Wealth Management LLC | unchanged | - | 3,091 | 14,091 | 0.01% |
May 16, 2024 | Tidal Investments LLC | new | - | 217,941 | 217,941 | -% |
May 16, 2024 | COMERICA BANK | reduced | -2.9 | 707,324 | 3,638,100 | 0.02% |
May 16, 2024 | Beacon Capital Management, LLC | sold off | -100 | -1,433 | - | -% |
May 16, 2024 | Pineridge Advisors LLC | sold off | -100 | -1,617 | - | -% |
May 16, 2024 | JANE STREET GROUP, LLC | reduced | -78.97 | -4,964,690 | 1,825,820 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -16.68 | 523,468 | 8,558,870 | 0.01% |
May 15, 2024 | INSIGNEO ADVISORY SERVICES, LLC | new | - | 210,144 | 210,144 | 0.03% |
May 15, 2024 | Cubist Systematic Strategies, LLC | sold off | -100 | -5,775,580 | - | -% |
May 15, 2024 | Quarry LP | sold off | -100 | -9,258 | - | -% |
Unveiling Bruker Corp's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Bruker Corp)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 181.0B | 40.3B | 32.18 | 4.49 | ||||
BDX | 68.3B | 19.7B | 51.24 | 3.46 | ||||
ALGN | 20.4B | 3.9B | 44.2 | 5.22 | ||||
BAX | 18.0B | 14.9B | 6.79 | 1.21 | ||||
MID-CAP | ||||||||
ATR | 9.8B | 3.5B | 31.27 | 2.76 | ||||
HSIC | 9.6B | 12.5B | 24.63 | 0.77 | ||||
BIO | 8.4B | 2.6B | -26.02 | 3.22 | ||||
XRAY | 5.9B | 3.9B | -62.84 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -216.3 | 8.9 | ||||
PDCO | 2.3B | 6.6B | 11.93 | 0.35 | ||||
SMALL-CAP | ||||||||
AHCO | 1.3B | 3.2B | -1.91 | 0.41 | ||||
ANIK | 376.6M | 169.3M | -4.9 | 2.23 | ||||
ANGO | 241.9M | 324.0M | -1.26 | 0.75 | ||||
APYX | 56.1M | 50.5M | -2.46 | 1.11 | ||||
AEMD | 1.0M | 3.7M | -0.09 | 0.28 |
Bruker Corp News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -15.5% | 722 | 855 | 743 | 682 | 685 | 708 | 639 | 588 | 595 | 684 | 609 | 571 | 555 | 628 | 511 | 425 | 424 | 600 | 521 | 490 | 461 |
Cost Of Revenue | -13.0% | 369 | 424 | 360 | 341 | 326 | 343 | 304 | 290 | 289 | 342 | 300 | 290 | 276 | 315 | 263 | 238 | 232 | 304 | 267 | 260 | 247 |
Gross Profit | -18.0% | 353 | 430 | 383 | 341 | 360 | 366 | 335 | 298 | 306 | 342 | 309 | 281 | 279 | 313 | 248 | 186 | 192 | 296 | 254 | 230 | 215 |
Operating Expenses | -11.9% | 288 | 327 | 258 | 254 | 237 | 235 | 204 | 224 | 210 | 216 | 196 | 195 | 190 | 200 | 167 | 148 | 176 | 179 | 166 | 177 | 173 |
S&GA Expenses | -7.5% | 195 | 211 | 178 | 178 | 163 | 165 | 145 | 152 | 146 | 153 | 141 | 135 | 132 | 130 | 115 | 102 | 121 | 130 | 125 | 125 | 120 |
R&D Expenses | -2.0% | 82.00 | 84.00 | 71.00 | 71.00 | 69.00 | 64.00 | 56.00 | 60.00 | 57.00 | 58.00 | 52.00 | 56.00 | 55.00 | 57.00 | 48.00 | 44.00 | 49.00 | 47.00 | 46.00 | 49.00 | 46.00 |
EBITDA Margin | -4.8% | 0.22* | 0.23* | 0.20* | 0.20* | 0.21* | 0.21* | 0.21* | 0.20* | 0.21* | 0.21* | 0.21* | 0.20* | - | - | - | - | - | - | - | - | - |
Income Taxes | -46.6% | 20.00 | 37.00 | 31.00 | 20.00 | 30.00 | 23.00 | 41.00 | 20.00 | 32.00 | 44.00 | 21.00 | 21.00 | 28.00 | 34.00 | 20.00 | 7.00 | 3.00 | 42.00 | 22.00 | 11.00 | 8.00 |
Earnings Before Taxes | -70.3% | 72.00 | 241 | 119 | 78.00 | 107 | 121 | 129 | 70.00 | 94.00 | 120 | 109 | 80.00 | 85.00 | 106 | 75.00 | 31.00 | 14.00 | 111 | 83.00 | 48.00 | 38.00 |
EBT Margin | -7.6% | 0.17* | 0.18* | 0.15* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.16* | 0.15* | - | - | - | - | - | - | - | - | - |
Net Income | -75.2% | 51.00 | 206 | 88.00 | 57.00 | 77.00 | 97.00 | 88.00 | 50.00 | 62.00 | 76.00 | 87.00 | 58.00 | 57.00 | 69.00 | 54.00 | 24.00 | 11.00 | 69.00 | 61.00 | 37.00 | 31.00 |
Net Income Margin | -7.1% | 0.13* | 0.14* | 0.11* | 0.12* | 0.12* | 0.12* | 0.11* | 0.11* | 0.11* | 0.11* | 0.11* | 0.10* | - | - | - | - | - | - | - | - | - |
Free Cashflow | -99.8% | 0.00 | 174 | 17.00 | -10.50 | 63.00 | 137 | 12.00 | -62.30 | 59.00 | 110 | 8.00 | -0.70 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | 6.0% | 4,506 | 4,250 | 3,820 | 3,857 | 3,764 | 3,612 | 3,337 | 3,385 | 3,551 | 3,650 | 3,128 | 3,087 | 3,035 | 3,049 | 2,879 | 2,943 | 2,962 | 2,772 | 2,352 | 2,350 | 2,243 |
Current Assets | -1.1% | 2,140 | 2,164 | 2,029 | 2,183 | 2,133 | 2,113 | 2,037 | 2,088 | 2,251 | 2,472 | 1,989 | 1,968 | 1,946 | 1,925 | 1,826 | 1,957 | 1,990 | 1,796 | 1,434 | 1,406 | 1,344 |
Cash Equivalents | -29.7% | 343 | 488 | 364 | 575 | 598 | 646 | 629 | 726 | 820 | 1,072 | 577 | 612 | 700 | 686 | 571 | 750 | 799 | 682 | 300 | 287 | 303 |
Inventory | 9.5% | 1,061 | 968 | 916 | 915 | 859 | 800 | 750 | 759 | 740 | 710 | 733 | 730 | 701 | 692 | 696 | 665 | 626 | 577 | 587 | 595 | 542 |
Net PPE | -2.3% | 586 | 600 | 527 | 523 | 511 | 487 | 422 | 395 | 404 | 406 | 389 | 398 | 384 | 396 | 355 | 336 | 319 | 306 | 278 | 282 | 268 |
Goodwill | 29.1% | 752 | 583 | 561 | 558 | 527 | 458 | 382 | 396 | 384 | 340 | 324 | 315 | 313 | 320 | 313 | 295 | 290 | 293 | 282 | 285 | 6.00 |
Liabilities | 7.7% | 3,056 | 2,837 | - | - | - | 2,480 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Liabilities | -1.6% | 1,183 | 1,202 | 1,072 | 1,051 | 1,049 | 914 | 865 | 818 | 881 | 939 | 921 | 955 | 944 | 792 | 683 | 750 | 766 | 646 | 643 | 641 | 633 |
Long Term Debt | 17.0% | 1,357 | 1,160 | 1,099 | 1,123 | 1,109 | 1,201 | 1,137 | 1,171 | 1,205 | 1,222 | 718 | 721 | 716 | 842 | 828 | 924 | 915 | 813 | 519 | 494 | 332 |
LT Debt, Non Current | -100.0% | - | 1,160 | 1,099 | 1,123 | 1,109 | 1,201 | 1,137 | 1,171 | 1,205 | 1,222 | 718 | 721 | 716 | 842 | 828 | 924 | 915 | 813 | 519 | 494 | - |
Shareholder's Equity | 4.0% | 1,433 | 1,377 | 1,209 | 1,251 | 1,199 | 1,114 | 948 | 984 | 1,031 | 1,085 | 1,090 | 1,015 | 982 | 974 | 963 | 907 | 925 | 917 | 855 | 870 | 922 |
Retained Earnings | 1.9% | 2,367 | 2,324 | - | - | - | 1,926 | - | - | - | 1,660 | - | - | - | 1,407 | - | - | - | 1,275 | - | - | - |
Additional Paid-In Capital | 2.9% | 291 | 283 | - | - | - | 256 | - | - | - | 238 | - | - | - | 216 | - | - | - | 200 | - | - | - |
Shares Outstanding | 0.1% | 145 | 145 | 146 | 147 | 147 | 147 | 147 | 148 | 149 | 151 | 152 | 151 | - | - | - | - | - | - | - | - | - |
Minority Interest | 1.1% | 18.00 | 17.00 | 18.00 | 20.00 | 19.00 | 12.00 | 11.00 | 14.00 | 14.00 | 14.00 | 14.00 | 13.00 | 14.00 | 13.00 | 11.00 | 9.00 | 9.00 | 10.00 | 10.00 | 9.00 | 8.00 |
Float | - | - | - | - | 6,099 | - | - | - | 4,001 | - | - | - | 4,040 | - | - | - | 2,173 | - | - | - | 5,068 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -89.4% | 21,800 | 205,500 | 44,100 | 13,000 | 87,500 | 171,500 | 69,500 | -44,400 | 77,800 | 138,600 | 23,900 | 21,900 | 98,000 | 203,000 | 82,400 | 11,800 | 35,000 | 136,200 | 52,400 | 10,600 | 14,200 |
Share Based Compensation | -14.5% | 5,300 | 6,200 | 5,700 | 5,600 | 6,500 | 4,700 | 5,300 | 9,700 | 8,000 | 5,300 | 4,200 | 3,900 | 3,800 | 5,100 | 4,500 | 3,100 | 3,300 | -500 | 4,000 | 3,000 | 3,100 |
Cashflow From Investing | -726.6% | -304,200 | -36,800 | -155,000 | -26,000 | -108,200 | -149,300 | -57,600 | 57,100 | -101,800 | -48,600 | -48,400 | -71,400 | -24,000 | -28,800 | -48,200 | -15,100 | -100,600 | -39,200 | -12,600 | -79,900 | -26,700 |
Cashflow From Financing | 353.3% | 151,700 | -59,900 | -92,500 | -10,300 | -30,700 | -36,100 | -82,000 | -79,800 | -217,400 | 404,300 | -2,600 | -44,900 | -38,100 | -74,300 | -225,500 | -53,100 | 191,300 | 277,900 | -19,500 | 50,400 | -8,800 |
Dividend Payments | 0% | 7,300 | 7,300 | 7,400 | 7,300 | 7,400 | 7,400 | 7,400 | 7,500 | 7,500 | 6,000 | 6,100 | 6,000 | 6,100 | 6,100 | 6,200 | 6,100 | 6,200 | 6,200 | 6,200 | 6,300 | 6,300 |
Buy Backs | -100.0% | - | 50,400 | 80,300 | 100 | 22,300 | 25,550 | 72,400 | 60,300 | 105,600 | 82,200 | - | 38,300 | 32,800 | 68,800 | 5,000 | 50,000 | - | - | 42,300 | 100,000 | - |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Total revenue | $ 721.7 | $ 685.3 |
Total cost of revenue | 368.9 | 325.6 |
Gross profit | 352.8 | 359.7 |
Operating expenses: | ||
Selling, general and administrative | 195.3 | 162.7 |
Research and development | 81.8 | 69.0 |
Other charges, net | 10.9 | 5.3 |
Total operating expenses | 288.0 | 237.0 |
Operating income | 64.8 | 122.7 |
Interest and other income (expense), net | 6.8 | (16.1) |
Income before income taxes, equity in income of unconsolidated investees, net of tax, and noncontrolling interests in consolidated subsidiaries | 71.6 | 106.6 |
Income tax provision | 19.8 | 29.9 |
Equity in income of unconsolidated investees, net of tax | 0.2 | 0.7 |
Net income | 52.0 | 77.4 |
Net income attributable to noncontrolling interests in consolidated subsidiaries | 1.1 | 0.9 |
Net income attributable to Bruker Corporation | $ 50.9 | $ 76.5 |
Net income per common share attributable to Bruker Corporation shareholders: | ||
Basic | $ 0.35 | $ 0.52 |
Diluted | $ 0.35 | $ 0.52 |
Weighted average common shares outstanding: | ||
Basic | 145.2 | 146.8 |
Diluted | 145.9 | 147.6 |
Product | ||
Total revenue | $ 586.9 | $ 567.1 |
Total cost of revenue | 291.7 | 257.2 |
Other | ||
Total revenue | 134.8 | 118.2 |
Total cost of revenue | $ 77.2 | $ 68.4 |
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 340.1 | $ 488.3 |
Accounts receivable, net | 475.4 | 492.0 |
Inventories | 1,060.5 | 968.3 |
Other current assets | 264.4 | 215.6 |
Total current assets | 2,140.4 | 2,164.2 |
Property, plant and equipment, net | 586.1 | 599.7 |
Goodwill | 751.9 | 582.6 |
Intangible assets, net | 449.2 | 330.5 |
Operating lease assets | 105.1 | 91.7 |
Deferred tax assets | 280.1 | 297.2 |
Other long-term assets | 193.6 | 184.0 |
Total assets | 4,506.4 | 4,249.9 |
Current liabilities: | ||
Current portion of long-term debt | 21.2 | 121.2 |
Accounts payable | 199.1 | 202.7 |
Deferred revenue and customer advances | 485.2 | 400.0 |
Other current liabilities | 477.0 | 478.2 |
Total current liabilities | 1,182.5 | 1,202.1 |
Long-term debt | 1,357.3 | 1,160.3 |
Long-term deferred revenue and customer advances | 105.6 | 91.5 |
Deferred tax liabilities | 81.8 | 67.7 |
Operating lease liabilities | 85.7 | 74.8 |
Accrued pension | 76.0 | 76.6 |
Other long-term liabilities | 166.7 | 163.6 |
Total liabilities | 3,055.6 | 2,836.6 |
Commitments and contingencies (Note 16) | ||
Redeemable noncontrolling interests | 17.9 | 18.7 |
Shareholders' equity: | ||
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding | 0.0 | 0.0 |
Common stock, $0.01 par value 260,000,000 shares authorized, 176,113,521 and 175,943,705 shares issued and 145,334,642 and 145,164,826 shares outstanding at March 31, 2024 and December 31, 2023, respectively. | 1.7 | 1.7 |
Treasury stock, at cost, 30,778,879 shares at March 31, 2024, and December 31, 2023, respectively | (1,237.2) | (1,237.2) |
Additional paid-in capital | 291.1 | 282.9 |
Retained earnings | 2,367.4 | 2,323.8 |
Accumulated other comprehensive (loss) income, net of tax | (7.7) | 6.0 |
Total shareholders' equity attributable to Bruker Corporation | 1,415.3 | 1,377.2 |
Noncontrolling interests in consolidated subsidiaries | 17.6 | 17.4 |
Total shareholders' equity | 1,432.9 | 1,394.6 |
Total liabilities, redeemable noncontrolling interests and shareholders' equity | $ 4,506.4 | $ 4,249.9 |